Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 17.72 -0.75 (-4.06%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Travere Therapeutics Inc < Previous 1 2 ... 4 5 6 7 8 9 10 11 Next > Travere Therapeutics to Report Second Quarter 2023 Financial Results July 20, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation July 17, 2023 Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session July 17, 2023 Via Benzinga Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics July 17, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Analyst Ratings for Travere Therapeutics June 07, 2023 Via Benzinga 11 Analysts Have This to Say About Travere Therapeutics May 22, 2023 Via Benzinga Recap: Travere Therapeutics Q1 Earnings May 04, 2023 Via Benzinga Earnings Scheduled For August 3, 2023 August 03, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. Via Benzinga 3 Small-Cap Stocks That Could Be Big-Time Winners July 22, 2023 These stocks come with significant risks. But they could generate huge returns over time. Via The Motley Fool Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan July 21, 2023 Travere Therapeutics shares have lost nearly 30% since early May. Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 July 21, 2023 Via Benzinga Expert Ratings for Travere Therapeutics July 18, 2023 Via Benzinga Earnings Outlook For Travere Therapeutics May 03, 2023 Via Benzinga Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals July 17, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire July 05, 2023 Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis. Via Investor's Business Daily Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023 June 08, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire 3 Biotech Stocks That Could Skyrocket in the Next 12 Months June 07, 2023 These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. Via InvestorPlace Travere Therapeutics to Present at Upcoming Investor Conferences June 01, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria May 31, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire 3 Biotech Stocks With Blockbuster Potential May 24, 2023 Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics. Via InvestorPlace Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 May 22, 2023 Via Benzinga Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports First Quarter 2023 Financial Results May 04, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session May 02, 2023 Via Benzinga Chegg, Community Health Systems, Metropolitan Bank And Other Big Stocks Moving Lower On Tuesday May 02, 2023 U.S. stocks traded lower, with the Dow Jones losing around 477 points on Tuesday. Here are some big stocks recording losses in today’s session. Via Benzinga INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm May 02, 2023 From The Schall Law Firm Via Business Wire Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test May 02, 2023 Travere was testing a treatment for FSGS, a condition that causes kidney scarring. Via Investor's Business Daily Travere Therapeutics' Rare Kidney Disease Drug Disappoints In Phase 3 Study, Analyst Says Efficacy Trends Suggest Potential Path Forward May 02, 2023 Travere Therapeutics Inc (NASDAQ: TVTX) announced Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 02, 2023 Via Benzinga < Previous 1 2 ... 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
